We have recently identified ZNF185 as a gene that is downregulated in prostate cancer (PCa), in part via epigenetic alteration, and maybe associated with disease progression. In this study, we cloned the ZNF185 cDNA from normal human prostate tissues and investigated its biological function. We show that ZNF185 is a novel actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein that localizes to F-actin structures, and is enriched at focal adhesions. We find that the NH 2 -terminal region, which we designate the actintargeting domain, facilitates ZNF185 binding to actin in vitro and is both necessary and sufficient to mediate actin-cytoskeleton targeting of ZNF185, whereas the LIM domain, which is localized in the COOH-terminus is dispensable for this phenomenon. Interestingly, ectopic expression of full-length ZNF185, but not a mutant lacking the actin-targeting domain, could suppress proliferation and anchorage-independent growth of PCa cells. Together, our data suggest that ZNF185 may function as a tumor-suppressor protein by associating with the actincytoskeleton.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed tumor and the second leading cause of cancer death in American men (Jemal et al., 2006) . The molecular mechanisms underlying PCa remains poorly understood. However, recent advances in high-throughput technologies have made it possible to perform global gene expression profiling analysis to identify genes related to cancer development and/or progression. A number of laboratories, including ours, have recently implemented DNA microarrays to analyse genes dysregulated in PCa (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Welsh et al., 2001; Rubin et al., 2002; Vanaja et al., 2003) . Identification of genes with such a strategy has been instrumental in advancing our understanding of the molecular basis of the malignancy and the discovery of potential biomarkers or prognostic markers.
One of the most interesting genes from our screen is ZNF185, which encodes an Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein markedly underexpressed in most of the confined prostate tumors, and especially in metastatic disease (Vanaja et al., 2003) . Transcriptional silencing of this gene is in part owing to epigenetic alteration and maybe associated with disease progression. In fact, as determined by the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, an average of 4.6-, 6.4-and 22.1-fold decrease in ZNF185 transcript level was observed in intermediate grade (Gleason score 6), high-grade (Gleason score 9) and metastatic tumors, respectively, when compared with benign epithelia (Vanaja et al., 2003) . In support of our observation in PCa, recent studies from other groups suggest that severely decreased levels of ZNF185 transcript are common in lung primary tumors as well as in head and neck squamous cell carcinoma (Gonzalez et al., 2003; Medina et al., 2005) . In lung tumors, the ZNF185 gene was identified as a transcriptional target of the Brg-1-containing human switch/ sucrose non-fermenting complex (Medina et al., 2005) . Thus, dysregulation of ZNF185 expression appears to be a frequent event in several tumor types suggesting a potential role of this gene in tumor development.
ZNF185 was originally isolated in an effort to identify transcripts from the DXS52 region on chromosome Xq28 using a positional cloning approach (Heiss et al., 1997) . This region is also reported to harbor a gene involved in PCa susceptibility (Xu et al., 1998) . ZNF185 mRNA expression was detected in several normal human tissues by Northern blot analysis, and was most abundant in the prostate. A ZNF185 cDNA encoding 452 amino-acid (a.a.) residues with a single C-terminallocated LIM domain was assembled based on the sequence of an expressed sequence tagged (EST) clone and a genomic DNA sequence (Heiss et al., 1997) . The LIM domain is a cysteine-and histidine-rich double zinc-finger motif named after the three-homeodomain proteins: Lin-l 1, Isl-1 and Mec-3 (Way and Chalfie, 1988; Freyd et al., 1990; Karlsson et al., 1990) . This domain is present in a wide range of proteins whose functions include many fundamental biological processes such as cell lineage specification, cytoskeleton organization and organ development (Dawid et al., 1998; Bach, 2000; Kadrmas and Beckerle, 2004) . In addition, some LIM domain-containing proteins are also involved in pathological processes such as oncogenesis (e.g. EPLIN, Testin and LMO4) (Maul and Chang, 1999; Tatarelli et al., 2000; Tobias et al., 2001; Visvader et al., 2001; Song et al., 2002; Sum et al., 2002; Garvalov et al., 2003) . As the full-length ZNF185 cDNA has not been experimentally cloned, the biological function of this LIM domain-containing protein and the pathological relevance in PCa is unknown.
In this study, we have cloned the ZNF185 cDNA from normal human prostate tissues, expressed the full-length protein and its various deletions and investigated the biological functions of the ZNF185 protein. Our observations suggest that ZNF185 is an actin-binding protein that associates with multiple actin-regulated structures including focal adhesions and possesses significant growth inhibitory activity. Given the frequent transcriptional silencing in several tumor tissues, ZNF185 may be a new tumor suppressor protein and play an important role in PCa development or progression.
Results
ZNF185 cDNA cloning, exon/intron structure and potential protein domains Sequencing analysis of the cloned RT-PCR product as described in Materials and methods showed that the cloned ZNF185 cDNA is capable of encoding a polypeptide of 689 residues. Two in-frame stop codons were found at À36 and À25 upstream of the putative translation start site and a poly-A adenylation signal was identified near the 3 0 -end ( Figure 1 ). Thus, this cDNA sequence appeared to contain the full-length protein-coding region of the ZNF185 gene. Analysis of the putative translated sequence confirmed that ZNF185 contains two zinc-finger motifs in the COOH-terminus that fit the consensus pattern of a LIM domain (CX 2 CX 16À23 HX 2 CX 2 CX 2 CX 16À21 CX 2 (C/H/D), where X is any a.a. residue (Figure 1a) . A potential PEST sequence was identified at 151-175 with PEST-FIND algorithm. The hydrophilic stretches of a.a. rich in P, E/D, S/T and is flanked by positively charged residues (R/K) are believed to confer susceptibility to rapid intracellular proteolysis (Rogers et al., 1986) . The ZNF185 protein showed no significant homology to other proteins beyond the LIM domain. A detailed exon/intron structure analysis ( Supplementary Table 1) suggests that the ZNF185 gene spans a region of about 60 kb in genomic DNA on chromosome Xq28. All of the putative exon/intron boundaries possess conserved splice acceptor and donor sequences. Exons 16 and 17 are duplicates, which are 92 and 82% identical at the nucleotide and peptide levels, respectively. An alignment of the encoded peptide sequences is shown (Figure 1b) . The imperfect repeats are relatively rich in proline residues (12%), which mostly appear in the form of putative SH3 domain-interacting consensus sequences (PXXP) and are fully conserved. The two halves of the human LIM domain are encoded by exons 21 and 22, respectively. The entire 3 0 -untranslated region (3 0 -UTR) is derived from exon 23, the last and the largest exon of this gene. Importantly, this cDNA contains additional exons in the 5 0 -end, which encodes an extended 144 a.a. residues in the NH 2 -terminus of the protein compared to the previously reported ZNF185 (Heiss et al., 1997) .
Evolutionary conservation of the ZNF185 LIM domain across species Blast searches using the peptide sequence of the ZNF185 human LIM domain against Nr (blastp) and EST databases (tblastn) led to the identification of putative ZNF185 orthologs in 10 other species. Alignment of the translated cDNA sequences indicated that the LIM domain is evolutionarily conserved across species and represented a 56 a.a. sequence motif (Supplementary Figure 1a) . The consensus composition of the LIM domain and a diagram depicting coordination of two zinc ions by the CCHC and CCCC zinc-finger motifs are shown (Supplementary Figure 1b) . The mouse, rat and dog share over 90% identical residues and 98% similarity with their human counterpart. The size and spacing of each zinc-finger of the LIM domain is also maintained. Phylogenetic analysis revealed that the LIM domain from the human is, as expected, more closely related to that of dog, mouse and rat than those of chicken and other sea animals (Supplementary Figure 1c) .
ZNF185 protein is associated with actin-cytoskeleton structures LIM domain-containing proteins participate in many cellular processes including the regulation of the actincytoskeleton. To begin understanding the function of ZNF185, we generated green fluorescent protein (GFP)-and Flag-tagged versions of ZNF185. Both expression plasmids expressed fusion proteins of predicted size upon transfection to the cultured cells as determined by Western blot analysis (Figure 2a ). We first examined the intracellular localization of GFP-ZNF185 in the PCa cell line DU145 by immunofluorescent (IF) staining and confocal microscopy. The results suggested that GFP-ZNF185 co-aligned with the F-actin network (Figure 2b ). Same patterns of staining were observed in Flag-ZNF185-transfected cells stained with anti-Flag antibody (Figure 2c ), suggesting that the NH 2 -terminal tags did not influence the localization of ZNF185. Next, we wanted to further examine the localization of endogenous ZNF185 in prostate epithelial cells. Preliminary study suggested that the affinity-purified polyclonal antibody we generated for ZNF185 is highly specific in recognizing Flag-or GFP-ZNF185 fusion proteins in transfected cells by IF staining (data not shown). Thus, we performed IF localization of endogenous ZNF185 in PC3 and DU145 cells with this antibody. Both cell lines expressed ZNF185 mRNA based on RT-PCR analysis, although ZNF185 is partially methylated in PC-3 (Vanaja et al., 2003) . Our results indicated that the antibody could specifically detect endogenous ZNF185, which also colocalize with F-actin in these cells (Figure 2d and data not shown). The above results together indicated that both ectopically expressed and endogenous ZNF185 are closely associated with actin-cytoskeleton structures in cultured prostate epithelial cells To better define the association of ZNF185 with the actin-cytoskeleton-related structures, we employed FR cells for further study because of their well-developed stress fibers and prominent focal adhesion structures. When expressed in these cells, ZNF185 was found mainly colocalized to F-actin stress fibers (Figure 2e ). In addition, ZNF185 appeared to be enriched at focal adhesions as indicated by colocalization with two wellknown focal adhesion proteins vinculin and paxillin, respectively (arrows, Figure 2f and g). Given its presence both along F-actin stress fibers and at focal adhesions, we set out to further examine ZNF185 association with actin-cytoskeleton-related structures. We stained GFP-ZNF185-expressing cells with phalloidin and anti-vinculin antibodies to simultaneously observe ZNF185 distribution relative to both stress fibers and focal adhesion-related structures. We found that, in addition to F-actin stress fibers and focal adhesions, ZNF185 is present at several other actincytoskeleton-related areas including filopodia/lamellipodia and the F-actin meshwork (Figure 3a) . In particular, ZNF185 is highly enriched at the nodal points of the orthogonal F-actin meshwork (I-III) and the junction area between the distal ends of F-actin stress fibers and focal adhesions (IV, V). Taken together, these data indicate that ZNF185 colocalizes with multiple actinregulated structures and also accumulates at sites of focal adhesions. Such close association of ZNF185 with F-actin prompted us to investigate the effect of cytoskeleton disruption on the localization of ZNF185. GFP-ZNF185-transfected FR cells were treated with cytochalasin B, an actin-depolymerizing agent, before staining. We found an apparent disruption of F-actin stress fibers in the treated cells and re-localization of vinculin from focal adhesions to the cytoplasm. However, ZNF185 remains colocalized with the remaining F-actin (Figure 3b ). Under the same treatment conditions, a more pronounced cytoskeletal disruption was observed in DU145 cells, in which the F-actin stress fibers were completely disassembled and F-actin staining was greatly reduced in intensity. Again, as in the FR cells, ZNF185 remains exclusively colocalized with disrupted F-actin, which appears as dot-like aggregates within the cell (Figure 3c ). Taken together, these data indicate that ZNF185 is associated with sites of polymerized actin and may directly interact with F-actin.
NH 2 -terminus region, but not the LIM domain, is required for actin-cytoskeleton targeting As our data suggest that ZNF185 is an actincytoskeleton-associated protein, we wanted to identify which domain/region in ZNF185 is responsible for intracellular targeting. To accomplish this, we made a series of ZNF185 truncation constructs fused to GFP including LIM-less, LIM-only, NH 2 -terminal half (Nt), COOH-terminal half (Ct) and NH 2 -terminal deletion (NtDel), which are schematically depicted in Figure 4a . Truncation mutants of ZNF185 were transfected into FR cells and their cellular distribution and ability to colocalize with F-actin was determined and summarized in Figure 4b . Similar to the full-length ZNF185 as shown previously, the LIM-less mutant also colocalized with these F-actin structures (Figure 4d ). Thus, it appears that the LIM domain is not required for targeting ZNF185 to F-actin. Consistent with this notion, the LIM-only construct showed diffuse nuclear and cytoplasmic distribution similar to what was observed with GFP expression alone (compare Figure  4e and c) . Thus, these data indicate that the F-actintargeting domain of ZNF185 resides outside the LIM domain.
We further mapped the region of ZNF185 that promotes its colocalization with F-actin. As can be seen, GFP fusion protein containing ZNF185 a.a. 1-338 was still able to colocalize with F-actin (compare Figure 4f with d and Figure 3a) . Moreover, mutant NtDel, which lacks a.a. 1-135, was unable to colocalize with F-actin structures (Figure 4g ). Similar localization pattern was observed for ZNF185 a.a. 339-689 (data not shown). Taken together, these results indicate that the region of ZNF185 that participates in its colocalization with F-actin lies within the NH 2 -terminal 135 a.a. residues.
NH 2 -terminal region of ZNF185 mediates intracellular targeting and F-actin binding The above data indicate that NH 2 -terminal 135 a.a. is necessary for normal intracellular localization. To determine if this region alone is sufficient to mediate actin-cytoskeleton targeting, we expressed GFP-ZNF185 1À135 in FR cells and determined if it could localize to F-actin. Indeed, GFP-ZNF185 1À135 was efficiently localized to F-actin stress fibers (Figure 5a ). Interestingly, distinct changes in the F-actin stress fiber structure were observed in ZNF185 1À135 -expressing cells. Most notably, ZNF185 1À135 expression was associated with thicker, but fewer and apparently disorganized, F-actin stress fibers suggesting enhanced bundling of actin filaments in these cells (Figure 5a , arrows). To further characterize its F-actin targeting property in PCa cells, DU145 cells transfected with ZNF185 1À135 and ZNF185 136À689 expression plasmids, respectively, were treated with cytochalasin B for 30 min before being processed for F-actin staining with phalloidin. We found that ZNF185 1À135 , but not ZNF185 136À689 , colocalized with phalloidin staining under cytoskeletal disruption (Figure 5b and c) similar to that observed with full-length ZNF185 protein (Figure 5d ). Taken together, these data confirmed that the NH 2 -terminal 135 a.a. of ZNF185 is both necessary and sufficient to target ZNF185 to actin-regulated structures. We therefore have named this region of ZNF185 the actin-targeting domain (ATD). 
ZNF185, an F-actin-binding tumor suppressor J-S Zhang et al
Because ZNF185 full-length protein and its ATD colocalize with F-actin even following depolymerization with cytochalasin B (Figure 3b, c and Figure 5b) , it is possible that this protein interacts directly with F-actin through its ATD. To investigate this possibility, we first performed an F-actin co-sedimentation assay using in vitro translated Flag-tagged ZNF185 proteins. In the absence of F-actin (Figure 5d, lanes 1 and 2) , full-length ZNF185 was only found in the supernatant (S). However, in the presence of F-actin (Figure 5d, lanes  3 and 4) , almost all of the ZNF185 were found associated with F-actin in the pellet (P). In contrast, but consistent with the IF data presented in Figure 4g , the ZNF185 mutant NtDel did not associate with the pelleted F-actin, but remained exclusively in the supernatant (Figure 5d, lanes 7 and 8) . To further demonstrate the interaction between ZNF185 and actin, F-actin co-sedimentation assays were performed with purified recombinant His-tagged ZNF185 proteins. Consistent with the data in Figure 5d , only the ZNF185 full-length protein was efficiently co-sedimented with F-actin, whereas its NH 2 -terminal deletion was exclusively detected in the soluble fraction (Figure 5e , compare lanes 4 and 8 to 5 and 9). For controls, the Figure 3g ) and the extensive colocalization of ZNF185 with the partially disrupted F-actin stress fibers. (c) Same experiment as in (b) was performed with DU145 cells. GFP-ZNF185-expressing cells were stained with TRITC-phalloidin to visualize F-actin. Note the stress fibers are completely disrupted after treatment, but ZNF185 remain colocalized with the dot-like residue F-actin.
actin-binding protein a-actinin (Figure 5e , lanes 2 and 6) largely co-sedimented with F-actin, whereas bovine serum albumin (BSA) (Figure 5e , lanes 3 and 7) did not. These data together with localization analysis using ZNF185 deletion mutants provide evidence that ZNF185 is a direct F-actin-binding protein through its ATD. 
Overexpression of ZNF185 inhibits PCa cells proliferation

ZNF185, an F-actin-binding tumor suppressor J-S Zhang et al
LNCaP cells. GFP-positive cells were enriched by cell sorting, and used for (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assays. We found overexpression of ZNF185 is associated with slower cell growth compared to vector control in this assay (Figure 6a ). We also In vitro-translated Flag-ZNF185 full-length protein and its NH 2 -terminal deletion (ZNF185 136À689 ) were used in an F-actin co-sedimentation assay as described in the Materials and methods. Supernatant (S) and pellet (P) fractions were prepared and resolved on 4-12% SDS-PAGE gels. Flag-ZNF185 proteins were detected by Western blot analysis with anti-Flag antibody (top panel). A duplicated set of gels was stained with Coomassie blue to show the successful sedimentation of F-actin (bottom panel). Lanes 1, 2, 5 and 6 were without polymerized-actin (PA) and lanes 3, 4, 7 and 8 were with PA. The protein bands corresponding to the Flag-ZNF185 1À689 -and ZNF185 136À689 -expressed proteins on the Western blot were identified by single-and double-lined arrows, respectively. The actin band in the Coomassie-blue-stained gel is identified by an arrowhead. (e) Coomassie-blue-stained gel showing a representative result of an F-actin co-sedimentation assay performed with recombinant His-tagged ZNF185 proteins. Supernatant (lanes 2-5) and pellet (lanes 6-9) fractions of co-sedimentation samples were resolved on a 4-12% SDS-PAGE gels. Lane 1: BioRad precision M r standard; lanes 2 and 6: a-actin (positive control); lanes 3 and 7: BSA (negative control); lanes 4,8: His-ZNF185 1À689 and lanes 5 and 9: His-ZNF185 136À689 . His-ZNF185 1À689 and ZNF185 136À689 protein bands were identified by single-and double-lined arrows, respectively, and the actin band by an arrowhead. BSA and a-actinin bands were marked with single and double asterisks, respectively.
extended this observation to the androgen-independent PCa cell line DU145. Having established ATD as the only actin-cytoskeleton targeting domain, we were also interested in determining if ATD is involved in ZNF185 regulatory activity. Therefore, we generated stable DU145 clones expressing GFP-fused ZNF185 fulllength as well as its ATD-deleted mutant using the procedure described in the Materials and methods. The results indicated that the proliferation rate of ZNF185 full-length-expressing cells was much slower as compared to the control vector (Figure 6b ). In contrast, the expression of ZNF185 lacking the ATD had little effect on cellular proliferation. The expression of GFP-ZNF185 fusion proteins in these cells was confirmed by Western blot analysis with anti-Flag and anti-GFP antibodies, respectively (Figure 6b, insets) . Lastly, we investigated the effect of ZNF185 on anchorageindependent growth using the DU145 stable clones in soft agar assays. As compared to vector control, fewer colonies were formed by GFP-ZNF185 full-lengthexpressing cells, whereas similar numbers of colonies were observed in cells expressing the GFP-ZNF185 lacking the ATD (Figure 6c ). Taken together, the results suggest that overexpression of ZNF185 suppressed both monolayer proliferation and anchorage-independent growth of PCa cells and that the ATD is crucial for its growth inhibitory activity.
Discussion
Although ZNF185 was identified almost 9 years ago, its biological function and disease relevance has not been examined. It is worth mentioning that the ZNF185 cDNA described here likely represents the first experimentally cloned human ZNF185 cDNA encoding a full-length protein. Importantly, our cDNA extended the 5 0 -end of the ZNF185 protein coding sequence corresponding to the actin-binding region or ATD. The ATD is necessary for both targeting of ZNF185 to actincytoskeleton and its growth regulatory activity, whereas the previously reported ZNF185 452 without the ATD possibly represents a protein isoform not associated with actin-cytoskeleton (Heiss et al., 1997) . The presence of ZNF185 mRNA isoforms was further demonstrated by semiquantitative RT-PCR analysis on a panel of 18 normal human tissues (Supplementary Figure 1a) . We observed the highest expression of various ZNF185 mRNA isoforms in normal prostate as previously shown by Northern blot (Heiss et al., 1997) . In agreement with the partial methylation status of ZNF185 (Vanaja et al., 2003) and the presence of additional mRNA isoforms, we have been able to detect the expression of different ZNF185 protein isorfoms in the several PCa cell lines using ZNF185-specific antibody (Supplementary Figure  1b) . Thus far, four major alternatively spliced mRNA isoforms in normal prostate have been identified, cloned and sequence verified (Supplementary Figure 1c) . Although the biochemical/functional similarities/differences of these protein isoforms remain to be established, the fact that all of them contain the first six exons encoding the ATD suggest that they may share the actin-binding property. stable clones expressing ZNF185 and its (ÀATD) deletion as GFP fusion proteins were assessed for proliferation in monolayer culture for the indicated number of days. Cell number at the indicated time points was shown as means7s.e. Data represent one of three independent experiments with similar results. The expression of GFP only (a), GFP-ZNF185 (b) and GFP-ZNF185 (-ATD) (c) in stable clones was confirmed by Western blot analysis with anti-GFP antibodies (inset). (c) The indicated DU145 stable expression clones were used for clonogenic growth in soft agar assay. Two thousands cells from each clone were plated in quadruplicate wells, and after 15 days, the number of colonies from 3 to 5 fields per well was counted. The mean number of colonies per field for each well was averaged for each construct and is shown with standard error. Gray bars indicate the number of bigger-sized colonies with diameter greater than 100 mm.
ZNF185, an F-actin-binding tumor suppressor J-S Zhang et al ZNF185 contains a single LIM domain in COOHterminus and shows no significant homology to any other proteins beyond the LIM domain and neither does it have any other recognizable domain such as postsynaptic density protein/discs-large protein/zonula domains that exist in some of the LIM proteins. Given the presence of an LIM domain emerging as a hallmark of proteins that can associate with both the actincytoskeleton and the transcriptional machinery (Labouesse and Georges-Labouesse, 2003; Kadrmas and Beckerle, 2004) , we started our functional characterization on ZNF185 by investigating its intracellular localization. We did not observe a significant localization of either ectopically expressed or endogenous ZNF185 within the nucleus, but instead found that ZNF185 is an actin-cytoskeleton-associated protein.
Compared to paxillin, zyxin, PINCH and Testin, a group of focal adhesion LIM domain-containing proteins, ZNF185 displayed a wider association with actin-cytoskeleton-based structures including extensive colocalization to F-actin stress fibers, and lamellipodia/ filopodia and was also concentrated within the actinfilament meshwork and focal adhesions. Despite the fact that cytoskeleton association is a common feature of many LIM domain-containing proteins, our data suggest that the LIM domain is not necessary for the targeting of ZNF185 to the actin-cytoskeleton. Although the ATD does not contain known actinbinding domain/motif (e.g. calponin homology domain) or possess any similarity to other known actin-binding domains, we provide several lines of experimental evidence that the ATD is indeed fully responsible for the actin-cytoskeleton link of ZNF185. First, deletion of the ATD abolished cytoskeleton targeting, suggesting that the ATD is the only actin-targeting domain within ZNF185. Second, the ATD is required for ZNF185 in vitro binding to F-actin. Third, the expression of ATD alone exclusively localized to stress fibers. Finally, the ATD is able to localize to phalloidin-stained areas in the disrupted cytoskeleton similar to ZNF185 full-length protein. Taken together, these results suggest that ZNF185 localization to actin-regulated structures is primarily mediated through a direct interaction of the ATD with F-actin. Thus, we have identified ATD as a previously uncharacterized actin-binding sequence. Although we have localized the actin-binding region to these first 135 a.a., further mutational analysis will be needed to determine in full-extent of the elements within this ATD that are required to bind actin.
The fact that expression of the ATD alone had profound influence on actin-cytoskeleton structure, such as formation of disorganized stress fiber and apparently enhanced bundling activity of F-actin, which is not observed with either ZNF185 full-length protein or ATD deletion, suggests that although the ATD has the ability to interact with actin-cytoskeleton, it is likely that it is unable to recruit other protein(s) as does the full-length protein, which are also necessary to maintain normal actin-cytoskeleton dynamics and thereby affect F-actin structures through dominant-negative effects. Indeed, several putative SH3 domain-binding sites were identified in ZNF185, which may facilitate interactions with SH3 domain-containing actin-cytoskeleton regulatory proteins (e.g. Nck, SRC, Abi, cortactin). Further structural and functional analyses and the identification of other ZNF185-interacting proteins will help elucidate its role in the regulation of actincytoskeletal dynamics.
It has been speculated that ZNF185 may be involved in the regulation of cellular proliferation and/or differentiation (Heiss et al., 1997) . The frequent transcriptional inactivation in various tumors also implicates a role of ZNF185 gene in tumorigenesis (Gonzalez et al., 2003; Vanaja et al., 2003; Medina et al., 2005; Wong et al., 2005) . Actin re-organization participates in aspects of cell proliferation including gene transcription and cytokinesis. In this study, we provided the first experimental evidence by showing that ZNF185 overexpression inhibited both anchoragedependent and -independent growth in PCa cells. Although the underlying molecular mechanisms by which ZNF185 suppresses PCa cell proliferation are currently unknown, the necessity for ZNF185 localization to the actin-cytoskeleton is required to suppress cancer cell proliferation, suggesting that the proper intracellular localization of ZNF185 might be critical for the growth-inhibitory function of ZNF185. Further biochemical and genetic analysis will be required in order to determine if other domains of ZNF185 also participate in the growth suppressive effects of ZNF185.
In summary, we find that ZNF185 is a novel actincytoskeleton-associated LIM domain-containing protein with potent growth regulatory activity. Overexpression of ZNF185 suppresses both monolayer and anchorage-independent PCa cell proliferation. Localization of ZNF185 to actin-cytoskeleton is mediated via its ATD, which is also required for the growth-suppressing activity. Given the frequently observed transcriptional silencing of ZNF185 in different tumors, we propose that ZNF185 functions as a tumor-suppressing protein by associating with and regulating actin cytoskeletal dynamics. Future studies, both functional and genetic/ epigenetic, will be required to further address the role of this gene in PCa development and progression.
Materials and methods
Cloning of ZNF185 cDNA To obtain the cDNA sequence of ZNF185, RT-PCR was employed with cDNA made from benign prostate tissues used as a template. Briefly, total RNA was extracted from benign prostate tissues with the Trizol regent (Invitrogen-Life Technologies, Carlsbad, CA, USA). Using gene-specific primer (5 0 -TCAAACAGGGAGGGAGGAG-3 0 ) located at 98-116 bp downstream of the putative translation stop codon based on published ZNF185 cDNA (Y09638), 2 mg of RNA were reverse transcribed and then subjected to PCR amplification with the high-fidelity Pfx polymerase and the following primers: 5 0 -CTGAATCAAGTGAGAGGAGA-3 0 and 5 0 -TTTGTCCAC GAGTCATCAG-3 0 (Figure 1, underlined) . PCR products were cloned into the pCR2.1 blunt vector (Invitrogen-Life Technologies). The cDNA insert from a candidate clone was fully sequenced using T7, SP6 and gene-specific primers. Oligo v6.1 software was used for oligonucleotide primer design and Sequencher4.1 program was used for the alignment and assembling of the cDNA sequence contigs.
Data mining and bioinformatics
The Genbank databases were used for sequence searches. The detailed exon/intron structure for ZNF185 was determined based on our cDNA sequence and the genomic DNA clone (U82671) using the Spidey program (www.ncbi.nlm.nih.gov/ IEB/Research/Ostell/Spidey). To identify the putative ZNF185 homologs from other species, blast searches were performed with peptide sequence of human ZNF185 LIM domain against Nr (Blastp) and EST (Tblastn) databases. The LIM domain regions of these cDNA were translated to peptide sequences and aligned to build contig/consensus sequences using PRETTY, in the GCG Wisconsin package. Alignment of the human LIM domain with its orthologs from other species was carried out using Evolution. UPGMA phylogram corrected with Kimura distance was drawn using GROWTREE from the same package.
Construction of ZNF185 expression plasmids
The translated region of ZNF185 was PCR amplified with the Pfx polymerase using the sequence verified pCR2.1-ZNF185. plasmid DNA as a template. The oligonucleotide primer sequences were as follows: 5 0 -GGAATTCATGAGTATCT CAGCTCTTG-3 0 (forward) and 5 0 -ACGCGTCGACTA GAAGAGCTTCTCATAGC-3 0 (reverse). The restriction sites for EcoRI/SalI (underlined) were incorporated into PCR primers to facilitate their subcloning into different vectors. PCR-amplified fragments were digested with EcoRI and SalI and cloned directionally into the corresponding sites of pCMV Flag-tagged vector Tag2b (Stratagene, La Jolla, CA, USA), NH 2 -terminal GFP fusion protein expression vector pEGFP C2 (BD Clontech, Palo Alto, CA, USA) and pET28a (Stratagene). ZNF185-truncated fragments were PCR amplified and subcloned using the same strategy. The a.a. residues encoded by each deletion fragment is specified in each experiment in the results below. The sequences and reading frame of all constructs were verified by direct DNA sequencing.
Cell culture and transfection
Human PCa cell lines (DU145, LNCaP and PC-3) were routinely maintained in RPMI-1640 with 5% fetal bovine serum (FBS). Normal rat skin fibroblast cell line FR was grown at 371C under a humidified atmosphere of 5% CO 2 in Dulbecco's modified Eagle's medium with 2 mM L-glutamine, 1.0 mM sodium pyruvate and 10% FBS. Transfections were performed with Fugene 6 (Roche Applied Science, Indianapolis, IN, USA) or Lipofactamine2000 (Invitrogen) following the manufacturer's protocols. For indirect IF staining, cells were cultured on 10-well 7 mm HTC Super Cured glass slides (Erie Scientific Company, Portsmouth, NH, USA). Where indicated, cells were grown on slides coated with fibronectin 10 mg/ml in phosphate-buffered saline (PBS) for 60 min.
Western blot analysis
Cell extracts were prepared in lyses buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM MgCl 2 , 1% Triton X-100) supplemented with Complete Protease Inhibitor cocktail (Roche Applied Science). Protein concentrations were quantified using DC-protein assay reagents (Bio-Rad Laboratories, Hercules, CA, USA). Total cellular protein (10 mg) was fractionated and transferred for Western blot analysis with anti-Flag (M2) antibody (Sigma-Aldrich, St Louis, MO, USA) or rabbit anti-GFP polyclonal antibody (AbCam Inc., Cambridge, MA, USA) or affinity-purified rabbit anti-ZNF185 antibody generated in this study using procedures described previously (Zhang et al., 2005) .
In vitro translation, recombinant protein purification and generation of ZNF185 polyclonal antibody Flag-ZNF185 expression plasmids were used for in vitro transcription/translation with T3 RNA polymerase as described previously (Zhang et al., 2001) . To generate recombinant His-tagged fusion proteins, pET28a-ZNF185 expression vectors were transformed into Escherichia coli strain BL21 cells (Invitrogen-Life Technologies). His-ZNF185 136À689 protein expression was induced by 1 mM isopropyl-D-thiogalactopyranoside (Stratagene). The cells were lysed and clarified by centrifugation. Soluble fraction was loaded on TALON resin columns Agarose (BD Clontech) in the presence of 50 mM sodium phosphate, pH 8.0, 25 mM imidazole, 300 mM NaCl and 0.1% Triton X-100 (equilibration/washing buffer). After washing, His-ZNF185 136À689 was eluted with elution buffer containing 250 mM imidazole, pH 8.0. His-ZNF1851 1À689 protein was produced via leaky expression by growth overnight at 251C and purified as described above. The purified recombinant proteins were dialysed against PBS with 50% glycerol and was quantified using Braford assay. Anti-serum to ZNF185 was generated in New Zealand white rabbit by immunization with recombinant GST-ZNF185 136À689 fusion protein. The immunoglobulin (Ig)G fraction of antiserum was further affinity purified with recombinant ZNF185 protein as described previously (Zhang et al., 2005) .
F-actin binding assays F-Actin co-sedimentation assays were performed with both in vitro translated Flag-ZNF185 and bacterially expressed recombinant ZNF185 proteins using the Actin-Binding Protein Biochem Kit (Cytoskeleton, Denver, CO, USA) following the manufacturer's recommendations. Briefly, lyophilized rabbit skeletal muscle actin was suspended in general actin buffer (5 mM Tris-HCl, pH 8.0, 0.2 mM CaCl 2 , 0.2 mM adenosine 5 0 triphosphate (ATP) and 0.5 mM dithiothreitol (DTT)). Actin filament assembly was induced by adding 1:10 volume of polymerization buffer to the actin stock in a final volume of 50 ml containing 5 mM Tris, pH 8.0, 0.2 mM CaCl 2 , 0.5 mM DTT, 100 mM KCl, 2 mM MgCl 2 and 1 mM ATP; this solution of actin (50 mM) was incubated for 60 min at 251C to allow polymerization to reach a steady state. Just before the co-sedimentation assay, in vitro translated Flag-ZNF185 or recombinant His-ZNF185 proteins were centrifuged (75 000 g, 45 min) to remove protein aggregates (Airfuge, Beckman Instruments, Palo Alto, CA, USA). Protein samples in the resulting supernatant (5 ml reaction mix for the in vitrotranslated Flag-ZNF185 proteins and 5 mg for the recombinant proteins) were incubated with F-actin in a total volume of 50 ml. After incubation for 30 min at room temperature, the samples were centrifuged (75 000 g, 30 min at 251C) to pellet the F-actin and associated proteins. The supernatant was carefully removed and 10 ml of 5 Â SDS loading buffer were added, whereas the pellets were directly re-suspended in 60 ml of 1 Â SDS loading buffer. The samples were resolved on SDS-PAGE gels and stained with Coomassie Brilliant Blue R250. For in vitro translated ZNF185 proteins, the gels were transferred to nitrocellulose membrane for Western blot analysis.
IF staining and confocal microscopy Cells were washed with PBS, fixed with freshly prepared 4% parafomaldehyde in PBS for 20 min and permeabilized with 0.1%. Triton X-100/PBS for 5 min. Where indicated, cells were treated with cytochalasin B (10 mg/ml) for 30 min before being processed for staining. The monoclonal anti-paxillin (BD Transduction Labs, CA, USA), anti-vinculin hVIN-1 (Sigma) and the anti-Flag (Sigma) antibodies were used at 1:400, 1:250 and 1:2000 dilutions, respectively. The affinity-purified ZNF185 polyclonal antibody (5 mg/ml) was used at dilution of 1:5000 and tetramethyl rhodamine isothiocynate (TRITC)-conjugated phalloidin (Molecular Probes, Eugene, OR, USA) at 1:40. Alexa Fluor647-or fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG and FITC-conjugated goat anti-rabbit IgG were used as secondary antibodies as specified in each experiment. After nuclear counter-staining with Hoechst 33258, the slides were mounted with coverslips using the ProLong antifade kit (Molecular Probes). The cells were observed under a LSM510 laser-scanning microscope (Carl Zeiss Inc., Oberkochen, Germany) using a C-Apochromat Â 63 (1.2W) objective.
Cell proliferation and colony assays
To determine the effect on cell proliferation in transiently transfected cells, Flag-ZNF185 or empty vector was cotransfected with pEGFP vector plasmid (at a ratio of 4:1) into LNCaP cells. Twenty-four hours after transfection, cells were trypsinized and GFP-expressing cells was isolated by fluorescence-activated cell sorting device (FACS Vintage Cell Sorter). Equal number of sorted cells (1 Â 10 4 /well) was seeded into 96-well plates. At indicated intervals, MTS assays were performed to measure cell growth from quadruplicate wells as described previously (Pan et al., 2003) . To generate stable expression clones, DU145 cells were transfected with GFP-ZNF185 1À689 , GFP-ZNF185 136À689 and control pEGFP C2 vector in 10 cm dish with Lipofecatmine 2000. After 24 h, cells were split into 2 Â 10 cm dishes and allowed to recover overnight before adding G418 (600 mg/ml) for selection of resistant clones. After selective growth for 2 months, GFPpositive cells were isolated by fluorescence cell sorting (FACS Vintage Cell Sorter, Becton Dickinson). Equal number of sorted cells (1 Â 10 4 /well) was seeded into 96-well plates. At intervals, cells were removed from quadruplicate wells and counted by trypan blue exclusion using a hemocytometer. Anchorage-independent growth was determined by assaying colony formation in soft agar. A single cell suspension of 2 Â 10 3 viable DU145 (stably expressing GFP-ZNF185 1À689 , GFP-ZNF185 136À689 or GFP vector) in 0.3% low melting point agar was plated onto a 2-ml base layer of hardened 0.6% agarose with same media composition. Cultures were allowed to grow for 15 days, and colonies were stained with 0.01% crystal violet. Data represent two independent experiments with three replica dishes per experiment.
